346 related articles for article (PubMed ID: 25649979)
21. Suberoylanilide hydroxamic acid represses glioma stem-like cells.
Hsu CC; Chang WC; Hsu TI; Liu JJ; Yeh SH; Wang JY; Liou JP; Ko CY; Chang KY; Chuang JY
J Biomed Sci; 2016 Nov; 23(1):81. PubMed ID: 27863490
[TBL] [Abstract][Full Text] [Related]
22. Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model.
Ugur HC; Ramakrishna N; Bello L; Menon LG; Kim SK; Black PM; Carroll RS
J Neurooncol; 2007 Jul; 83(3):267-75. PubMed ID: 17310267
[TBL] [Abstract][Full Text] [Related]
23. Histone deacetylase inhibitors suppress the growth of human osteosarcomas in vitro and in vivo.
Wu Z; Ma C; Shan Z; Ju Y; Li S; Zhao Q
J BUON; 2013; 18(4):1032-7. PubMed ID: 24344034
[TBL] [Abstract][Full Text] [Related]
24. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells.
Xu XD; Yang L; Zheng LY; Pan YY; Cao ZF; Zhang ZQ; Zhou QS; Yang B; Cao C
BMC Cancer; 2014 May; 14():373. PubMed ID: 24886166
[TBL] [Abstract][Full Text] [Related]
25. Growth-suppressive effect of suberoylanilide hydroxamic acid (SAHA) on human oral cancer cells.
Jang B; Shin JA; Kim YS; Kim JY; Yi HK; Park IS; Cho NP; Cho SD
Cell Oncol (Dordr); 2016 Feb; 39(1):79-87. PubMed ID: 26582320
[TBL] [Abstract][Full Text] [Related]
26. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
[TBL] [Abstract][Full Text] [Related]
27. SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line.
Bellarosa D; Bressan A; Bigioni M; Parlani M; Maggi CA; Binaschi M
Int J Oncol; 2012 Oct; 41(4):1486-94. PubMed ID: 22797667
[TBL] [Abstract][Full Text] [Related]
28. A novel suberoylanilide hydroxamic acid histone deacetylase inhibitor derivative, N25, exhibiting improved antitumor activity in both human U251 and H460 cells.
Zhang S; Huang WB; Wu L; Wang LY; Ye LB; Feng BH
Asian Pac J Cancer Prev; 2014; 15(10):4331-8. PubMed ID: 24935393
[TBL] [Abstract][Full Text] [Related]
29. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
30. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
Zhang C; Richon V; Ni X; Talpur R; Duvic M
J Invest Dermatol; 2005 Nov; 125(5):1045-52. PubMed ID: 16297208
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
Luong QT; O'Kelly J; Braunstein GD; Hershman JM; Koeffler HP
Clin Cancer Res; 2006 Sep; 12(18):5570-7. PubMed ID: 17000694
[TBL] [Abstract][Full Text] [Related]
32. [Inhibitory Effect of Histone Deacetylase Inhibitor SAHA on Proliferation of Mouse Multiple Myeloma Cell Line SP2/0 in vitro and in vivo].
Huo L; Zhang CY; Dang YF; Zhang WJ; Liu MM; Liu LS; Zhu ZM; Fang N; Ji SP; Sun K
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):470-476. PubMed ID: 29665918
[TBL] [Abstract][Full Text] [Related]
33. Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines.
Asgar MA; Senawong G; Sripa B; Senawong T
Int J Oncol; 2016 Jan; 48(1):409-20. PubMed ID: 26575528
[TBL] [Abstract][Full Text] [Related]
34. Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR Signaling.
Zhang P; Guo Z; Wu Y; Hu R; Du J; He X; Jiao X; Zhu X
PLoS One; 2015; 10(8):e0136193. PubMed ID: 26287365
[TBL] [Abstract][Full Text] [Related]
35. BRD4 inhibitor and histone deacetylase inhibitor synergistically inhibit the proliferation of gallbladder cancer in vitro and in vivo.
Liu S; Li F; Pan L; Yang Z; Shu Y; Lv W; Dong P; Gong W
Cancer Sci; 2019 Aug; 110(8):2493-2506. PubMed ID: 31215139
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits anti-inflammatory activities through induction of mitochondrial damage and apoptosis in activated lymphocytes.
Shi ZJ; Ouyang DY; Zhu JS; Xu LH; He XH
Int Immunopharmacol; 2012 Apr; 12(4):580-7. PubMed ID: 22369900
[TBL] [Abstract][Full Text] [Related]
37. Synergistic suppressive effect of PARP-1 inhibitor PJ34 and HDAC inhibitor SAHA on proliferation of liver cancer cells.
Liang BY; Xiong M; Ji GB; Zhang EL; Zhang ZY; Dong KS; Chen XP; Huang ZY
J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):535-540. PubMed ID: 26223923
[TBL] [Abstract][Full Text] [Related]
38. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
Tang YA; Wen WL; Chang JW; Wei TT; Tan YH; Salunke S; Chen CT; Chen CS; Wang YC
PLoS One; 2010 Sep; 5(9):e12417. PubMed ID: 20856855
[TBL] [Abstract][Full Text] [Related]
39. Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model.
Kurundkar D; Srivastava RK; Chaudhary SC; Ballestas ME; Kopelovich L; Elmets CA; Athar M
Toxicol Appl Pharmacol; 2013 Jan; 266(2):233-44. PubMed ID: 23147569
[TBL] [Abstract][Full Text] [Related]
40. A novel harmine derivative, N-(4-(hydroxycarbamoyl)benzyl)-1-(4- methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxamide (HBC), as histone deacetylase inhibitor: in vitro antiproliferation, apoptosis induction, cell cycle arrest, and antimetastatic effects.
Miao JF; Peng YF; Chen S; Gao WJ; Yang QX; Zhu P; Guo J; Tao J; Luo L; Zhang Y; Ling Y
Eur J Pharmacol; 2018 Apr; 824():78-88. PubMed ID: 29428472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
